Tech company SARB has won a stay of orders barring it from selling its sensor-based system which the city of Melbourne uses for timing parked vehicles, after a judge found it infringed rival Vehicle Management Systems’ patent.
Tech company Vehicle Management Systems has won a long-running patent infringement dispute with rival SARB over a sensor-based system the City of Melbourne uses for timing parked vehicles.
Apple can argue an Australian non-practicing entity that claims its patents for a remote entry system were infringed by the tech company’s Touch ID and Face ID technology are invalid because of a Hewlett Packard handheld device that was first sold in 2000.
Pharmaceutical giant Pfizer has fired off a lawsuit against four drug companies for allegedly infringing one of its patents for biologic Enbrel by selling a biosimilar of the blockbuster arthritis drug in Australia.
An Australian designer of a trendy neoprene handbag sold at high-end department stores has lost an appeal which challenged a judge’s finding that its flagship bag was not a work of artistic craftsmanship.
The Full Court has upheld two judgments that shortened patent term extensions granted to Merck Sharpe & Dohme and Ono Pharmaceuticals, finding the extension regime cannot be construed as achieving a “commercial outcome for a patentee”.
Five years into a preliminary discovery application for a potential patent infringement lawsuit over a biosimilar of its Enbrel medication, Pfizer has partially succeeded in obtaining further documents from Samsung Bioepis.
Drug company Ono Pharmaceutical has faced tough questioning by an appeals court in a fight with IP Australia over a decision that secured it a patent extension for its cancer immunotherapy drug Opdivo.
IP Australia has appealed a ruling granting drug company Ono Pharmaceutical a patent extension for a cancer immunotherapy drug, calling it an “impermissible gloss” on the Patents Act that is at odds with the law’s purpose.
A judge has overturned a ruling from the Australian Patent Office that shortened the amount of time available to companies under patent term extensions, saying a “liberal rather than literal” reading was needed to achieve the extension regime’s goals of compensating holders of drug patents for the lengthy time required to obtain regulatory approval to market their drugs.